Ontralfy Solution
Product Images NDC 69528-310

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Ontralfy (NDC 69528-310). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rosemont Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label (Ontralfy 473 mL Label)

Bottle Label (Ontralfy 473 mL Label)
Label for Ontralfy, tizanidine oral solution, 2 mg/5 mL, 16 fl. oz. (473 mL) bottle. Includes dosage instructions to see prescribing information and pharmacist dispensing instructions for a tight, child-resistant container. Manufactured for Rosemont Pharmaceuticals, LLC, Greenville, SC. Features a barcode and storage temperature guidance.*
FDA Label Image

Chemical Structure (Ontralfy 01)

Chemical Structure (Ontralfy 01)
Chemical structure of Tizanidine Hydrochloride, showing its distinct molecular arrangement with chlorine, sulfur, nitrogen atoms and the hydrochloride component.*
FDA Label Image

Figure 1 (Ontralfy 02)

Figure 1 (Ontralfy 02)
A line graph depicting the improvement in Ashworth Score over time (Hours Post-Dose) comparing 16 mg tizanidine, 8 mg tizanidine, and placebo groups. The graph shows a peak in improvement around 2 to 3 hours post-dose, with 16 mg tizanidine having the highest improvement followed by 8 mg tizanidine and placebo showing minimal change.*
FDA Label Image

Figure 2 (Ontralfy 03)

Figure 2 (Ontralfy 03)
A line graph comparing the improvement in Ashworth Score over time between tizanidine (mean dose 28.8 mg) and placebo groups. The x-axis shows study weeks: end of titration (week 3), end of maintenance (week 7), and endpoint (last observation carried forward). The y-axis shows improvement in Ashworth Score, with tizanidine showing greater improvement than placebo at all time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.